Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To the Editor, As T cell-mediated immunotherapies are being explored as a treatment strategy for relapsed and refractory chronic lymphocytic leukemia (CLL), the study of autologous T cells in patients with CLL has intensified [1, 2]. The repertoire of αβ T cell receptors (TRA/TRB repertoire) in CLL patients exhibits several abnormalities.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
